KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZN) EBITDA (2016 - 2025)

Historic EBITDA for Astrazeneca (AZN) over the last 16 years, with Q4 2025 value amounting to $2.8 billion.

  • Astrazeneca's EBITDA rose 260360.36% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.9 billion, marking a year-over-year increase of 10725.85%. This contributed to the annual value of $12.9 billion for FY2025, which is 10727.45% up from last year.
  • Latest data reveals that Astrazeneca reported EBITDA of $2.8 billion as of Q4 2025, which was up 260360.36% from $2.6 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's EBITDA peaked at $4.0 billion during Q1 2025, and registered a low of -$974.0 million during Q3 2022.
  • Moreover, its 5-year median value for EBITDA was $1.6 billion (2022), whereas its average is $1.3 billion.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 19515.15% in 2022, then skyrocketed by 260360.36% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's EBITDA stood at -$746.0 million in 2021, then soared by 329.62% to $1.7 billion in 2022, then increased by 3.91% to $1.8 billion in 2023, then plummeted by 106.24% to -$111.0 million in 2024, then skyrocketed by 2603.6% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q4 2025, $2.6 billion for Q3 2025, and $3.6 billion during Q2 2025.